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Abstract 
Background: Vitamin D levels have been linked to certain pain states, including migraine. We investigated 
whether vitamin D supplementation would be beneficial for adult patients with migraine (ClinicalTrials.gov 
Identifier: NCT01695460). 
 
Methods: A randomized, double-blind, placebo-controlled parallel trial was conducted in migraine patients (36 
women and 12 men, 18-65 years of age). A 4-week baseline period was conducted before randomization to 24 
weeks of treatment. Participants were assigned to receive D3-Vitamin® (n=24, 18 women and 6 men, 100 
μg/day D3-Vitamin®) or placebo (n=24, 18 women and 6 men). Migraine attacks and related symptoms were 
assessed by self-reported diaries. The response rate (i.e., experiencing a 50 % or greater reduction in migraine 
frequency from baseline to week 24), change in migraine severity, and number of migraine days were 
recorded. Changes in migraine-related symptoms, HIT-6TM scores, and pain sensitivity tests (pressure pain 
threshold and temporal summation) were also evaluated. Serum levels of both 25(OH)D and 1,25(OH)2D were 
assessed from baseline to week 24. 
Results: The number of headache days changed from 6.14±3.60 in the treatment group and 5.72±4.52 in the 
placebo group at baseline to 3.28±3.24 and 4.93±3.24 by the end of the trial, respectively. Migraine patients on 
D3-Vitamin® demonstrated a significant decrease (p<0.001) in migraine frequency from baseline to week 24 
compared with placebo. However, migraine severity, pressure pain thresholds or temporal summation did not 
show a significant change. 25(OH)D levels increased significantly for the D3-Vitamin® group during the first 12 
weeks of treatment. There was no significant change in 1,25(OH)2D. No side effects were reported or noted. 
Conclusions: D3-Vitamin® was superior to placebo in reducing migraine days in migraine patients. Larger 
studies are required to confirm that vitamin D3 might be one of the prophylactic options for adult patients with 
migraine. 
Key words: Vitamin D; migraine; 25(OH)D; 1,25(OH)2D; pain; headache   
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Introduction 
Migraine is a highly prevalent, complex primary headache, affecting women more than men [1]. This disabling 
disorder is characterized by spontaneous headache attacks often accompanied by nausea, vomiting, and 
sensitivity to light [2, 3]. A large number of migraineurs also experience allodynia, a sensation of pain in 
response to normally non-noxious stimuli [4]. The exact pathogenesis of migraine is unclear, but the general 
consensus is that migraine is a result of a complex neurovascular imbalance [5, 6, 7]. Migraine has remained 
undertreated [8]. Usually, the goal of abortive therapy is to block headache, while the goal of prophylactic 
therapy is to reduce migraine attack frequency, severity, or disease progression [9]. Some common migraine 
prophylactics include anticonvulsants, beta-blockers, and tricyclic antidepressants [9]. A number of vitamins, 
minerals, and medicinal herbs have also been considered, including riboflavin, magnesium, and vitamin D [10, 
11]. Insufficiency or deficiency of vitamin D has been linked to several painful disorders, including headaches 
[12]. In general, however, the results are inconclusive, and causal relationships are not established [12, 13, 14, 
15, 16]. Vitamin D insufficiency and deficiency are very common in the general population due to several 
factors, including inadequate sun exposure, inadequate intake, inadequate internal synthesis, or genetic 
variances in vitamin D metabolism [17, 18]. We hypothesized that vitamin D3 supplementation in a 
randomized, parallel, double-blinded, placebo-controlled trial could prove effective in adult patients with 
migraine. 
Materials and Methods 
Participants and visits 
The study was conducted in accordance with guidelines from Good Clinical Practice and the Declaration of 
Helsinki and approved by the local Ethics Committee, Region North Jutland, Denmark (N-20120052). The trial 
was also registered with ClinicalTrials.gov (Identifier: NCT01695460). 
Subjects were recruited through advertisement on public notice boards, on Netdoktor.dk and forsog.dk, and 
furthermore through advertisement on social networks (Facebook). Subjects eligible for screening were 
screened by the study neurologists at Aalborg Hospital North, Denmark. Prior to enrollment, all subjects 
provided written informed consent. All follow-up visits took place at CCBR A/S Aalborg, Denmark, within the 
time period of 2012-2016. 
The sample size calculation resulted in N≈20, meaning that 20 migraineurs were needed in each treatment arm 
to ensure adequate statistical power. To adjust for an expected dropout rate of 20 %, we aimed at recruiting 24 
migraineurs in each treatment arm, in total, 48 migraineurs; 36 women and 12 men, taking into account the 
natural distribution of sexes in the migraine population [1]. 
Migraine diagnosis was based on criteria set by the International Headache Society for headache classification 
(ICHD-II). Migraineurs within the age range of 18-65 years with migraine onset before the age of 50 years were 
included. The exclusion criteria included other neurological or neurodegenerative disorders, medical conditions 
that could potentially interfere with the study, a history of severe head trauma or stroke, musculoskeletal or 
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psychiatric disorders, ongoing treatment with digoxin or thiazides, existing hypercalcemia, and use of vitamin D 
supplementation in doses higher than 10 μg/day. Experiencing aura was not used for exclusion. 
For each subject, the study lasted 196 days and consisted of 8 visits at 4-week intervals (± 3 days). This 
flexibility was applied to allow for holidays and to ensure that subjects were headache-free during visits. 
Initially, the subjects were followed for a baseline period of 4 weeks, after which they were randomized 1:1 to 
receive either vitamin D3 supplementation (100 μg daily) or placebo for 24 weeks. Subjects were required to be 
headache-free at visits 1, 2, 5, and 8 because this could have an influence on sensory assessments. The visits 
included blood sampling, the Headache Impact Test 6 (HIT-6TM) questionnaire, measuring vital signs (blood 
pressure, pulse, and oral temperature), and quantitative sensory tests (pressure pain threshold (PPT) and 
temporal summation). An overview of these procedures for each visit is shown in Table 1. All procedures were 
performed by the same members of the study group for each subject. 
 
Subjects kept diaries for each migraine attack that was reviewed by the investigators at each visit. In this diary, 
patients recorded headache occurrence, duration, and severity. Severity was rated on a 1-2-3 scale, referring to 
mild (=1), moderate (=2), and severe (=3) headache. Furthermore, the presence of aura, nausea, photo- and 
phonophobia, and allodynia (feeling pain during nonpainful stimuli, such as brushing hair), and the use of 
abortive therapy were recorded in the diary. Based on the ethical guidelines, participants continued to use 
their migraine medications but were asked to record and report it. No restrictions were applied. 
Medications 
Subjects were randomized to receive 24 weeks of treatment with either vitamin D3 supplementation (D3-
Vitamin®, 100 μg/day) or placebo. The dose and treatment duration chosen in this study were based on the 
following rationales. The dose should have ensured high enough increases in serum 25(OH)D levels to exclude 
variations due to diet and exposure to sunlight. An effect should have not been evaluated until a steady state 
of 25(OH)D had been reached and maintained for some time, and therefore the treatment period was 
important, as the half-life of vitamin D3 (2-3 weeks) and hence the time to reach steady state is quite long. The 
treatment period was also important in evaluating migraine. Treatment periods of three to six months are 
recommended in migraine trial guidelines as it provides more stable estimates of attack frequency [19]. 
Women and men were randomized separately to ensure an equal distribution of each sex in each treatment 
arm. Randomization was performed based on randomly generated codes in blocks of four, i.e., per four 
subjects, two received D3-Vitamin® and two received placebo. Four tablets were administered orally once per 
day, each containing either 25 μg vitamin D3 or placebo (consisting of tablet excipients). Both D3-Vitamin® and 
placebo tablets were obtained from D3-Pharmacy ApS (Aalborg, Denmark). Placebo tablets and the D3-
Vitamin® tablets were identical. Treatment was initiated at week 0. Study medication was handed out 6 times; 
at weeks 0, 4, 8, 12, 16, and 20, i.e., medication for only 4 weeks at a time. Each pill bottle contained 150 
tablets, thus ensuring that there were enough tablets even if a visit was rescheduled for a few days late, e.g., in 
case that the subject suffered a migraine attack. Pill bottles were returned with leftover tablets at every 
following visit. A tablet count was performed to follow up on compliance with study medication. The subjects 
were made aware of the importance of taking the study medication correctly. Subjects were instructed that 
Ac
c
pt
ed
 M
an
us
cr
ipt
 
any missed dose should be taken the same day, immediately when the subject recalled it. They were not 
allowed to take it the following day. The agreeable limit of compliance was 85 %, meaning that subjects had to 
have taken at least 85 % of study medication. Leftover study medication was destroyed following completion of 
the study. A blinded clinical research assistant who did not take part in any other activities provided pills to 
participants. We ensured that participants and investigators as well as study staff assessing outcomes at visits 
or entering data after visits remained blinded to treatments. 
It is well recognized that vitamin D has a desirable safety profile and very limited potential side effects [20]. 
However, adverse events were recorded during the study. 
Primary and secondary outcomes 
This study was conducted to investigate the efficacy of vitamin D3 (100 μg/day) against migraine in comparison 
with placebo. The primary efficacy measures were whether and how migraine frequency and severity (pain 
intensity) could be altered by vitamin D3 supplementation. Primary efficacy measures were change in migraine 
attack frequency, number of days with migraine, and severity. Changes from baseline to the last four weeks of 
the treatment and through the entire double-blind phase were compared between the two treatment groups. 
Responders were considered those who had a 50 % or greater reduction in migraine attack frequency from 
baseline to the last four weeks of treatment. 
Secondary efficacy measures included changes from baseline to the last four weeks of treatment in migraine-
related symptoms, including aura, nausea, photo- and phonophobia, and allodynia, changes in HIT-6TM scores 
and responses to quantitative sensory tests. 
We also investigated whether and how daily vitamin D3 supplementation could alter serum levels of vitamin D, 
both 25(OH)D and 1,25(OH)2D. Vitamin D has two forms: vitamin D2 (ergocalciferol) and D3 (cholecalciferol), 
which undergo identical metabolism. The major circulating form of vitamin D is 25(OH)D, which is hydroxylated 
in the kidneys to the biologically active form 1,25(OH)2D, which interacts with the vitamin D receptor. Vitamin 
D status is determined by measuring the precursor 25(OH)D. There are several reasons for this: 1,25(OH)2D 
circulates in concentrations that are 1000 times less than 25(OH)D, and 25(OH)D is a more stable vitamin D 
metabolite because it has a half-life of approximately 2-3 weeks (43,50). Furthermore, 1,25(OH)2D is tightly 
regulated, and only very small concentrations of 25(OH)D are necessary for maintaining sufficient levels of 
1,25(OH)D [21]. Interestingly, no studies have investigated a correlation between 1,25(OH)2D and 25(OH)D 
before and after supplementation with vitamin D3 to determine whether supplementation can cause an 
increase in serum 1,25(OH)2D levels as well as in serum 25(OH)D levels. Therefore, we considered measuring 
both. 
Below, more details are given for the assessments. 
Headache Diary 
A diary was given to each patient with a guide for completing it. Date and time at onset of the attack and its 
termination time were included. 
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For the description of the headache aura and the experienced disturbances, the timing was also asked. 
Location and intensity of headache were also included (on a scale of 1 to 3, in which 1=mild headache, 
2=moderate headache, and 3=severe headache). Other symptoms and a short description of those were also 
included. To record the presence of allodynia, we asked whether the patients experienced increased pain or 
unpleasant sensations on the skin and when this occurred (i.e., during the headache or between attacks). 
Examples of allodynia included combing hair, pulling hair back (e.g., ponytail), shaving face, wearing eyeglasses, 
wearing contact lenses, wearing earrings, wearing a necklace, wearing tight clothing, taking a shower (when 
shower water hits facial skin), resting head or face on a pillow, exposure to heat (e.g., cooking, washing face 
with hot water), and exposure to cold (e.g., using an ice pack, washing face with cold water). Type, dose and 
frequency of medications taken for migraine were also included in the diary. Data obtained from diaries were 
extracted and recorded in a case report form (CRF) for each patient. 
 
Headache Impact Test 
HIT-6TM was created by QualityMetric Incorporated (USA) as a tool to assess and monitor disease burden, 
including the impact of migraine on functional health and well-being, i.e., quality of life. The HIT-6TM 
questionnaire was provided to each subject at three visits during the course of the study (See Table 1). The 
questionnaire provides a score from 36 to 78, indicating the degree to which the subject’s quality of life is 
affected by migraine. A score above 60 indicates severe impact, 56-59 indicates substantial impact, 50-55 
indicates some impact, and a score below 50 indicates only little or no impact of migraine on quality of life. HIT-
6TM was used to investigate whether the impact on quality of life by migraine changed during the course of the 
study. 
 
Quantitative Sensory Tests 
PPT and temporal summation were assessed to record hypersensitivity and to determine whether these 
measures changed during the course of the study, i.e., following treatment. Both tests were performed on each 
side of the head on the temporal muscle, on both arms, at a point on the belly of the brachioradialis muscle, 
and on the right leg, at a point located on the belly of the tibialis anterior muscle 5 cm distal to the tibial 
tuberosity. PPT was performed on a point on the temporal muscle as determined as the most sensitive point 
for migraineurs [22]. This point is located 1.5 cm above the upper medial edge of the ear and 1 cm anterior 
from there. For temporal summation, a point on the hairless part of the temple was used. During both tests, 
the subject was lying comfortably on their side, for test points on the head, and on the back, for test points on 
the limbs. 
At the first visit, the location of the points on the limbs was noted to retrieve the same points at the following 
visits. To ensure that the same point was used every time, the distance from the radial styloid process to the 
test point was measured and noted for both arms. On the right leg, the distance from the lateral malleolus of 
the fibula to the test point was measured. These measurements were then used during the following visits to 
mark the test points.  
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Pressure Pain Threshold 
The pressure pain threshold is used to assess the minimal amount of pressure needed to evoke a pain response 
in the subject. PPT was performed using a handheld pressure algometer (Somedic AB, Hörby, Sweden) 
consisting of a 1 cm2 rubber-tipped probe. The probe was placed perpendicularly on the test points. Pressure 
was applied at a rate of 30 kPa/s, and subjects were instructed to push a stop button immediately when they 
defined the pressure as painful. Pressure stimulation was stopped, and the maximum pressure was noted. 
Three consecutive PPTs were performed on each test point with a minimum of 10 seconds in between. A mean 
of the three measurements was calculated for each test point. A 25 % deviation from the mean of the three 
PPTs was used to eliminate outliers, i.e., If a PPT measurement was outside this limit, a new PPT measurement 
was performed. The mean value was used for subsequent statistical analysis. 
Temporal summation 
 
Temporal summation, a clinical correlate of wind-up related to central sensitization, is a frequency-dependent 
increase in the excitability of spinal and trigeminal neurons [23, 24]. The test was performed with the use of a 
customized PinPrick stimulator (Aalborg University, Denmark) that exerts a force of 128 mN. For safety 
reasons, 128 mN was used as the maximum force. For each test site, all stimuli were applied within an area of 1 
cm2. First, a single stimulus was applied by the PinPrick stimulator. Immediately hereafter, the subject was 
asked to rate the intensity of the stimuli on a 0 to 10 numerical scale, with 0 being “no pain” and 10 being 
“worst possible pain”. After a period of 10 seconds, a series of 10 identical punctuate stimuli with a frequency 
of one stimulation per second were performed, and again, the subject was asked to rate the intensity of the 
stimuli on the numerical scale. From these ratings, the difference between the single stimulus and the series of 
stimuli was calculated. The test was performed twice for each test point. The mean of the differences was 
calculated and used for further statistical analysis. Only data from patients with a change in rating from the 
single stimulus to the 10 consecutive stimuli were included in the data analysis for temporal summation. 
 
Blood sampling and serum analysis 
Blood samples were drawn from an antecubital vein using a hypodermic needle (21G, BD Vacutainer® Safety-
Lok™, #368654, Becton Dickinson AB, Stockholm, Sweden) and collected in 5 mL serum separation tubes (BD 
Vacutainer® SST II Plus, #367955, Becton Dickinson AB, Stockholm, Sweden), while the subject sat in a 
comfortable position. During visits 1, 2, 5, and 8, three blood samples were drawn, one of which served as a 
backup sample. The blood samples were turned upside down 5- 6 times manually to ensure that the sample 
was thoroughly mixed with the clot activator in the serum separation tube. The samples were then left for a 
minimum of 30 minutes to allow clotting before being centrifuged at 3000 rpm for 10 minutes at 20°C. For each 
serum separation tube, the supernatant serum was transferred to a transfer tube. The transfer tubes were kept 
at -80°C until further analysis. Serum was analyzed for 25(OH)D and 1,25(OH)2D by chemiluminescence enzyme 
immunoassay using an IDS-iSYS Fully Automated Immunoassay System.  
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Data analysis 
Data were analyzed using SPSS Version 22. A P-value ≤ 0.05 was considered statistically significant. Normal 
distributions of data were assessed by means of the Shapiro-Wilks test. If P>0.05, the data were considered to 
be normally distributed. An independent-samples t-test, or the nonparametric equivalent (Mann-Whitney U 
test), was used to test for baseline equality and uniformity between the two groups, i.e., the D3-Vitamin® 
group and the placebo group, regarding age and migraine characteristics. 
The responder rate was evaluated using a chi-squared test. Two-sample t-tests were used for comparisons 
between the treatment group and the placebo group regarding remaining primary endpoints. For 
nonparametric data, the Mann-Whitney U test was applied. Primary efficacy measures were also analyzed in 
the individual treatment groups by means of the paired samples t-test. For nonparametric data, the Wilcoxon 
signed-rank test was applied. Descriptive data were presented for migraine-related symptoms. McNemar’s test 
was used to assess the presence of migraine-related symptoms before and after treatment in the individual 
treatment groups. Repeated measures analysis of variance (RM ANOVA) was used for comparison of changes 
across time within and between the two treatment groups for HIT-6TM, quantitative sensory tests, and changes 
in serum levels of 25(OH)D and 1,25(OH)2D. For nonparametric data, Friedman’s test was applied. Spearman’s 
correlations for nonparametric data were used to assess potential correlations between serum levels of 
25(OH)D and 1,25(OH)2D at baseline and week 24. 
 
Results 
This study screened 65 participants, among whom 48 were identified as eligible and enrolled (36 women, 12 
men, 18-65 years). Forty-eight subjects completed the study. Participants were randomly assigned to receive 
D3-Vitamin® (n=24, 18 women and 6 men) or placebo (n=24, 18 women and 6 men). We had 2 dropouts who 
were both in the placebo group, and discontinuation was due to personal choice and not for any medical 
reasons; therefore, we replaced these two participants (Flowchart 1). No adverse events were reported, and 
compliance levels were above 85 %. All subjects were Caucasian, from Nordic countries, and residents of 
Denmark. 
Within- and between-group differences in the use of migraine medication were not significantly different. The 
type and dose of medications also remained generally stable for both groups. Assessment of blinding at weeks 
12 and 24 by James’ blinding index [25] showed successful overall blinding. 
The demographic and baseline characteristics of the study participants are summarized in Table 2. There were 
no significant differences between the two groups at baseline, and the baseline mean level of serum 25(OH)D 
was within the optimal level (75-125 nmol/L).  
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Primary efficacy measures 
Responders were those with a 50 % or greater reduction in migraine attack frequency from baseline to week 
24. A significant difference was found between the two groups (P=0.008), with higher responder rates in the 
D3-vitamin® group. A summary of the primary efficacy measures is presented in Table 3. 
 
From baseline to week 24, the median change in migraine severity on a 1-2-3 scale did not show any 
statistically significant difference between the two groups (P=0. 823, Mann-Whitney U test). The mean 
reduction in the number of migraine days from baseline to week 24 was higher in the D3-Vitamin® group 
compared with the placebo group (P=0.047). 
For the D3-Vitamin® group, the Friedman test showed a significant change across time in attack frequency 
(P=0.014). Regarding the severity of attacks, the Friedman test did not reveal a significant change across time 
(P=0.621); however, the number of migraine days was affected (P=0.012). For the placebo group, the Friedman 
test did not show a significant change across time in either attack frequency (P=0.059) or severity (P=0.614). 
The repeated measures ANOVA for the number of migraine days also did not show a significant change across 
time in this group (P=0.548). 
Secondary efficacy measures 
The proportions of subjects experiencing migraine-related symptoms during baseline and week 24 in the 
individual treatment groups were evaluated, and no significant change was observed (McNemar’s test, Table 
4). 
The mean HIT-6TM scores for each treatment group at each time point were evaluated. Repeated measures 
ANOVA with treatment as the between subject factor was conducted to compare HIT-6TM scores between the 
D3-Vitamin® group and the placebo group over time. There was no significant main effect across time 
(P=0.520). No significant difference was evident in the change across time between the two treatment groups 
(P=0.227). However, in both groups, the score showed a decrease over time. For the D3-Vitamin® group, it was 
from 
63.25±4.17 from first measure (visit 2) to 53 in last (visit 8), and for the placebo group, it was from 62.75±5.31 
to 56.83. 
Quantitative sensory tests were employed to assess hyperalgesia and central sensitization. Repeated measures 
ANOVA and the nonparametric equivalent Friedman test showed that there were no significant changes in PPT 
levels at any test or time point, neither for the D3-Vitamin® group nor the placebo group (P>0.05). For 
temporal summation, repeated measures ANOVA and the Friedman test showed that there was no significant 
change across time at any test point (P>0.05).  
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Serum analysis 
For 25(OH)D, a repeated measures ANOVA with Greenhouse-Geisser correction revealed a significant main 
effect for time (P<0.001) and a significant difference in the change across time between the two treatment 
groups (P<0.001). In the D3-Vitamin® group, there was an increase in mean serum 25(OH)D levels at week 24 
compared with baseline. This increase across time was statistically significant (P=0.003, the Friedman test). The 
major change in the D3-Vitamin® group occurred between the start of intervention and week 12 (Wilcoxon’s 
signed-rank test, P=0.043), i.e., during the first 12 weeks of treatment. After week 12, the rate of increase in 
serum 25(OH)D levels leveled off, and there was no significant change from week 12 to week 24 (Wilcoxon’s 
signed-rank test, P=0.080). The mean serum 25(OH)D levels in the placebo group did not show a significant 
change from baseline to week 24 (P=0.781, repeated measures ANOVA). 
We also tested whether a correlation existed between serum levels of 25(OH)D and 1,25(OH)2D at baseline and 
at week 24. According to Spearman’s rho, there was no significant correlation between 25(OH)D and 
1,25(OH)2D at baseline (P=0.384) or at week 24 (P=0.285). We performed both unadjusted analyses and 
adjusted analysis for baseline values, age, and body mass index. Regression models indicated similar outcomes 
independent of baseline values, age, or body mass index. 
Discussion 
This study demonstrated that D3-Vitamin® was superior to placebo in reducing migraine attacks in adults with 
migraine. 
Headache and associated characteristics 
A Norwegian study assessed vitamin D status in patients with musculoskeletal pain, fatigue and headache [15]. 
Vitamin D deficiency was found in 58 % of those patients. A cross-sectional study also showed that in a British 
population, chronic widespread pain was associated with low levels of 25(OH)D in females. However, no such 
association was evident for male subjects [26]. In contrast, the European Male Ageing Study (n=3075) found 
that subjects classified as having either chronic widespread pain or “other pain” had significantly lower mean 
levels of 25(OH)D [27]. We did not find any vitamin D deficiency among our participants at the start of the 
study. However, all participants were diagnosed with migraine based on the IHC criteria. Therefore, we tested 
our hypothesis that vitamin D supplementation might have an effect on migraine and demonstrated that D3-
Vitamin® was superior to placebo in the reduction of migraine attacks in adults with migraine. 
Previously, two case report studies had shown that vitamin D was effective in reducing the frequency of 
migraine in four women [28, 29]. One of these studies included two premenopausal women suffering from 
menstrual migraine and premenstrual syndrome, and the other included two postmenopausal women 
suffering from migraine. All four subjects were treated with a combination of vitamin D2 or D3 and calcium in 
varying doses. During these studies, all four subjects reported a decrease in frequency and duration of migraine 
attacks. The two premenopausal women also reported a relief of premenstrual syndrome, including related 
pain symptoms. Our findings also demonstrated a decrease in the frequency of migraine. A recent study has 
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also demonstrated that simvastatin and vitamin D were effective in preventing headache in adults with 
episodic migraine [30]. 
Although the nature of our study does not allow for a discussion of the exact mechanism underlying the 
observed effect, one explanation might be the anti-inflammatory effects of vitamin D, which could affect 
neuroinflammation associated with migraine [31]. Studies have shown that vitamin D, at physiologic levels, can 
suppress the production of proinflammatory cytokines such as IL-6 and tumor necrosis factor-α in human 
monocytes and macrophages [32]. In relation to this, it has been shown that in migraine patients, serum levels 
of these proinflammatory cytokines are higher compared to healthy controls [33, 34]. Vitamin D has also been 
shown to cause an increase in the production of the anti-inflammatory cytokine IL-10 by cells that are involved 
in the immune response [35]. IL-10 has been shown to be lower in migraine patients compared to healthy 
controls [34]. Vitamin D, in the active form 1,25(OH)2D, can inhibit the synthesis of inducible nitric oxide 
synthase, which generates NO [36, 37]. In relation to this, it has been shown that NO can stimulate the 
synthesis and release of CGRP from trigeminal ganglion neurons, and it is known that CGRP stimulates the 
release of NO from trigeminal ganglion cells. Thus, this might lead to a positive feedback loop that can enhance 
and maintain inflammatory processes within the sensory ganglion, which could contribute to sensitization of 
meningeal nociceptors during migraine [38, 39]. Taken together, these findings suggest that vitamin D has an 
anti-inflammatory effect that could influence migraine. 
Analysis of migraine-related symptoms, i.e., aura, nausea, photo- and phonophobia, and allodynia showed no 
significant pattern of change across time for either group (D3-Vitamin® and placebo) in this study. The quality 
of life questionnaire HIT-6TM showed that both groups were severely affected by migraine at baseline, with the 
D3-Vitamin® group having slightly, but not significantly, higher baseline scores compared with the placebo 
group. Both groups improved during the treatment period, but the reduction was not significant. The fact that 
both groups presented a similar pattern might be explained by the placebo effect that is often observed in 
migraine trials [40]. Quantifying the placebo response in migraine indicates that these responses are common 
in migraine, especially in parallel-designed studies of prophylactic agents [40]. When applying HIT-6TM scores as 
a measure of quality of life in studies regarding migraine prophylactics, it should be considered that HIT-6TM 
scores are affected greatly by the severity of migraine attacks and not so much by the frequency [41]. 
Therefore, another quality of life assessment tool in combination with HIT-6TM might be better, for example, 
the migraine disability assessment (MIDAS) questionnaire. 
Pressure pain threshold and temporal summation 
The PPT test was employed to investigate whether PPT changed during the treatment period, i.e., whether PPT 
was affected by vitamin D3 supplementation. In this study, PPT was assessed as a measure of hyperalgesia, 
which has been demonstrated in migraineurs [22]. However, in this study, there was no significant change 
across time, for either the D3-Vitamin® group or the placebo group. Temporal summation was also assessed as 
the clinical correlate of wind-up, which is related to central sensitization. Similar to the PPT results, there was 
no significant change across time for either the D3-Vitamin® group or the placebo group at any test point. A 
study has demonstrated the presence of higher temporal summation in migraineurs between attacks 
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compared with healthy controls [42]. The authors suggested that migraineurs have altered membrane 
excitability and hence increased pain production, which is also present between attacks. 
Serum analysis for 25(OH)D and 1,25(OH)2D levels 
Serum 25(OH)D levels increased significantly following vitamin D3 supplementation. The most notable increase 
occurred between week 0 and week 12, and the rate of increase then leveled off from week 12 to 24. The 
results showed a significant increase in serum 25(OH)D levels in the treatment group. However, no significant 
change in serum 1,25(OH)2D was observed. As 1,25(OH)2D has a half-life of approximately four to six hours 
[43], this might explain why no change was observed across the four time points that only represent snapshots 
in sampling time. When looking at raw data, there is great variation between individual subjects and within 
subjects at the different time points. 1,25(OH)2D was measured to investigate whether there was a correlation 
between serum levels of the two metabolites. To the best of our knowledge, this has not previously been 
investigated before and after vitamin D3 supplementation. Only small concentrations of 25(OH)D are necessary 
for maintaining sufficient levels of 1,25(OH)2D [21]. However, if severe vitamin D deficiency (25(OH)D) was 
observed, then 1,25(OH)2D might also be deficient. We also did not find a correlation between 1,25(OH)2D and 
25(OH)D (neither at baseline nor following supplementation with vitamin D3). If a positive correlation had been 
observed following vitamin D3 supplementation, concern might have been raised in relation to the risk of 
developing hypercalcemia [20]. There is a risk of side effects manifested as hypercalcemia when high doses of 
vitamin D3 are administered. However, the risk is considered low with regard to the dose administered in this 
study (100 μg/day), since several studies involving healthy men and women receiving this dose did not report 
hypercalcemia, even when supplementation was administered for longer periods of up to 14 months [44, 45]. 
Because the risk was considered low in this study, calcium was not measured. 
In our study, the D3-Vitamin® group reached serum levels above the optimal level; however, serum levels were 
still well below those considered potentially toxic. None of our participants reported any adverse effects, and 
the treatments were well tolerated. Vitamin D3 is considered safe and has a very limited side effect profile [20] 
in comparison with existing migraine prophylactic agents. Vitamin D3 supplementation is also relatively 
inexpensive and is available as an over-the-counter medication in many regions. Hence, it is an attractive agent 
for the prophylaxis of migraine. 
Study limitations 
Participants in this study were all Danish, balanced at enrollment and had similar migraine features. Therefore, 
although the main finding is promising, studies in a larger and more diverse population are required to identify 
whether this finding can be replicated. In this population, we did not have enough power to analyze sex-related 
differences in the efficacy of D3-Vitamin® versus placebo. It should be noted that migraine attacks might be 
triggered by various factors. Hormonal changes, stress, not eating, and sleep disturbances are among them [46, 
47]. Trigger factors were not used for any subanalyses in this study. 
In prophylactic migraine trials, most studies permit migraine medication, as recommended by guidelines [19]. 
In this study, migraine medication was also allowed. Two of our subjects were on concomitant prophylactic 
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therapy, and they did not alter the dosage or regimen during the study (one subject received Lamictal® and 
propranolol, and one subject received amitriptyline). 
Conclusion 
A significant reduction in the frequency of attacks over time was evident in migraine patients treated with D3-
Vitamin®. Migraine-related symptoms were not significantly affected by the supplementation, nor were pain 
thresholds and sensitivity affected. Quality of life, measured by HIT-6TM, did not show a significant 
improvement. One hundred micrograms/day D3-Vitamin® was effective in raising serum 25(OH)D levels. No 
change was observed in serum 1,25(OH)2D levels. Considering the reduction of headache frequency and safety 
profile of D3-Vitamin® observed in this study, we propose considering this agent as one of the prophylactic 
options in adult patients with migraine. This needs to be proven in a larger trial. 
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Tables  
Table 1. An overview of procedures performed at each visit  
 Visit 1 
Week -4 
Visit 2 
Week 0 
Visit 3 
Week 4 
Visit 4 
Week 8 
Visit 5 
Week 12 
Visit 6 
Week 16 
Visit 7 
Week 20 
Visit 8 
Week 24 
Duration  60 60 20 20 60 20 20 60 
Blood  x x   x   x 
HIT-6
TM
   x   x   x 
Vital signs x x x x x x x x 
QST x x   x   x 
 
HIT-6TM: Headache Impact Test 6, Vital signs: Blood pressure, pulse, and temperature; QST (quantitative 
sensory tests): Pressure pain threshold and temporal summation. Duration of visits is indicated in minutes.   
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Flowchart 1. Patient flow diagram. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assessed for eligibility (n=65) 
Excluded  (n= 17) 
   Not meeting inclusion criteria (n= 17) 
   Declined to participate (n= 0) 
   Other reasons (n= 0) 
Analysed  (n=48) 18 women, 6 men 
 Excluded from analysis (n=0) 
Lost to follow-up (give reasons) (n=0) 
Discontinued intervention (personal reasons) 
(n= 2), which were replaced (n=2) 
Allocated to Placebo (n= 24) 
 Received allocated intervention (n= 24) 
 Did not receive allocated intervention (n= 0) 
Lost to follow-up (give reasons) (n= 0) 
Discontinued intervention (give reasons) (n= 0) 
Allocated to D3-Vitamin® (n=24) 
 Received allocated intervention (n=24) 
 Did not receive allocated intervention (n=0) 
Analysed  (n=48) 18 women, 6 men 
 Excluded from analysis (n= 0) 
 
Allocation 
Analysis 
Follow-Up 
Randomized (n= 48) 
Enrollment 
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Table 2. Demographic characteristics of the study participants at baseline  
 
Characteristics at baseline 
D3-Vitamin® group 
(n=24) 
18 women, 6 men 
Placebo group 
(n=24) 
18 women, 6 men 
 
P value 
Age (years) 45.5±12.1 43.7±10.2 0.634 
Frequency of migraine attacks  4.0 4.0 0.802 
Severity of migraine attacks 2.64±1.20 2.38±1.90 0.831 
Number of migraine days 6.14±3.60 5.72±4.52 0.322 
HIT-6TM score 63.25±4.17 62.75±5.31 0.872 
25(OH)D (nmol/L) 87.43±32.00 78.96±30.86 0.548 
1,25(OH)2D (pg/mL) 
 
43.55±10.57 43.71±11.60 0.834 
 
Except data for frequency (median), all data are shown as mean ± SD (standard deviation), HIT-6TM = Headache 
Impact Test-6. P-values are given for comparison of baseline levels between the two groups, and analyzed 
using an independent samples t-test. For frequency of migraine attacks, non-parametric equivalent, Mann-
Whitney U test, was utilized. P ≤ 0.05 are considered statistically significant. 
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Table 3: Summary of primary efficacy measures  
 
Primary outcome 
D3-Vitamin® group 
(n=24) 
18 women, 6 men 
Placebo group 
(n=24) 
18 women, 6 men 
Attack frequency    
Week 0 
 
3.00±1.07 
 
3.75±1.98 
 
Week 1-4 
 
2.73±1.23 
 
2.33±2.13 
 
Week 5-8 
 
2.88±1.25 
 
3.12±1.88 
 
Week 9-12 
 
1.53±1.66 
 
3.68±1.06 
 
Week 13-16 
 
1.38±1.77 3.70±1.22 
 
Week 17-20 
 
1.26±1.72 
 
3.93±2.51 
 
Week 21-24 
 
1.29±1.03 
 
3.57±1.92 
Attack severity     
Week 0 
 
2.16±0.45 
 
2.29±0.53 
 
Week 1-4 
 
2.26±0.27 
 
2.16±0.23 
 
Week 5-8 
 
2.12±0.14 
 
2.33±1.23 
 
Week 9-12 
 
1.88±1.07 
 
2.19±0.58 
 
Week 13-16 
 
1.64±1.24 
 
2.15±0.54 
 
Week 17-20 
 
1.73±1.05 
 
1.83±1.82 
 
Week 21-24 
 
1.87±1.32 
 
1.79±0.95 
Number of days with migraine    
Week 0 
 
6.25±4.00 
 
6.13±3.36 
 
Week 1-4 
 
4.88±1.96 
 
5.25±3.77 
 
Week 5-8 
 
4.15±2.32 
 
5.88±2.85 
 
Week 9-12 
 
3.75±3.37 
 
4.75±1.83 
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Week 13-16 
 
3.88±2.21 
 
4.75±1.25 
Week 17-20 
 
3.89±3.64 
 
4.53±3.78 
 
Week 21-24 
 
3.28±3.24 
 
4.93±3.24 
 
 
Attack severity was rated as 1=mild headache, 2=moderate headache, and 3=severe headache. Data are 
presented as mean±SD (standard deviation). 
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Table 4: Presence of migraine-related symptoms  
Migraine related symptoms  D3-Vitamin® group 
(n=24) 
18 women, 6 men 
Placebo group 
(n=24) 
18 women, 6 men 
Aura   
        Baseline 12. 2% 12.5% 
        Week 21-24 10.4% 10.3% 
        P-value 0.534 0.367 
Nausea   
        Baseline 27.3% 26.4% 
        Week 21-24 25.9% 26.1% 
        P-value 0.574 0.531 
Photophobia   
        Baseline 9.5% 8.4% 
        Week 21-24 8.1% 7.2% 
        P-value 0.721 0.834 
Phonophobia   
        Baseline 4.4% 3.8% 
        Week 21-24 3.7% 4.1% 
        P-value 0.545 0.457 
Allodynia   
        Baseline 21.7% 20.5% 
        Week 21-24 19.6% 18.8% 
        P-value 0.574 0.631 
 
P-values are given for a change in the presence of migraine related symptoms from baseline to week 21-24 for 
the individual treatment groups (McNemar’s test). 
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